AnaptysBio Balance Sheet Health
Financial Health criteria checks 5/6
AnaptysBio has a total shareholder equity of $88.1M and total debt of $310.8M, which brings its debt-to-equity ratio to 352.8%. Its total assets and total liabilities are $452.4M and $364.3M respectively.
Key information
352.8%
Debt to equity ratio
US$310.81m
Debt
Interest coverage ratio | n/a |
Cash | US$390.90m |
Equity | US$88.10m |
Total liabilities | US$364.29m |
Total assets | US$452.39m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AN6's short term assets ($406.8M) exceed its short term liabilities ($37.4M).
Long Term Liabilities: AN6's short term assets ($406.8M) exceed its long term liabilities ($326.8M).
Debt to Equity History and Analysis
Debt Level: AN6 has more cash than its total debt.
Reducing Debt: AN6's debt to equity ratio has increased from 1.6% to 352.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AN6 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AN6 has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 15.1% each year.